Related Experiment Video

Updated: May 31, 2025

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

312

Oridonin Suppresses the Malignant Progression of Lung Cancer by Targeting S100A11

Yulin Luo1,2, Jingjing Li1,2, Yao Chen2

  • 1Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P.R. China.

Current Medicinal Chemistry
|January 24, 2025
PubMed
Abstract

Insights

Oridonin, a natural compound, effectively inhibits lung cancer (LC) cell growth and metastasis. This study reveals that oridonin targets S100A11, offering a potential new strategy for treating this lethal cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Lung cancer (LC) is a leading cause of cancer mortality with limited effective treatments.
  • The pathogenic mechanisms of LC require further elucidation.
  • Oridonin, from Rabdosia rubescens, shows anticancer potential, but its role in LC is unexplored.

Purpose of the Study:

  • To investigate the effects of oridonin on lung cancer progression.
  • To elucidate the underlying molecular mechanisms of oridonin's action in LC.
  • To identify potential therapeutic targets for oridonin in LC treatment.

Main Methods:

  • Cell proliferation and migration assays (CCK8, EdU, Transwell, wound healing) were performed on A549 and Hcc1833 cells treated with oridonin.
  • In vivo models (subcutaneous tumor, caudal vein metastasis) assessed oridonin's efficacy against tumor growth and metastasis.
  • Proteomics, LiP-SMap, microscale thermophoresis, and molecular docking identified oridonin's interaction with S100A11.

Main Results:

  • Oridonin dose-dependently suppressed lung cancer cell proliferation and migration.
  • In vivo studies confirmed oridonin's inhibition of tumor growth and metastasis.
  • Oridonin directly interacted with the Asn-53 residue of S100A11, inhibiting its activation; S100A11 overexpression counteracted oridonin's effects.

Conclusions:

  • Oridonin exhibits significant anti-lung cancer activity.
  • The study identifies S100A11 as a key molecular target of oridonin in lung cancer.
  • Targeting S100A11 with oridonin presents a promising therapeutic strategy for lung cancer.
Keywords:
OridoninmS100A11lung cancermalignant progressionmicroscale thermophoresismolecular docking.

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

16.8K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K